DURHAM, NC, and LIEGE, BELGIUM - July 11, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDx(TM) for Brain) was shown to be the only prognostic factor for overall survival (OS) in newly diagnosed glioblastoma multiforme (GBM) patients over the age of 70 in a study published in the Journal of Clinical Oncology (JCO)*, one of the leading cancer journals. Prognostic factors are biological markers that help determine the course and outcome of disease. The study was conducted by eight of the foremost French academic institutions to evaluate the efficacy and safety of temozolomide alone in what is considered a fragile patient population, suffering from this devastating type of brain cancer.

The authors conclude that treatment with temozolomide has an acceptable safety profile and is associated with a significant improvement of functional status in one third of patients and appears to increase survival compared with supportive care alone. Remarkably, the only prognostic factor identified by the authors was MGMT promoter methylation status, which is linked to a substantially better outcome in patients with methylation (overall survival of 31 weeks) compared to patients without methylation (overall survival of 19 weeks).

"This study confirms the results of a steadily increasing number of clinical trial reports that support the importance of MDxHealth's PredictMDx for Brain test in clinical decision making," said Dr. Jan Groen, CEO of MDxHealth. "It also lends further support to the outcome of the large international temozolomide Phase III study (RTOG 0525), which was recently presented at the Annual Meeting of the American Society for Clinical Oncology. Validation of our MGMT assay through publications in prestigious peer-reviewed journals such as JCO also aids our discussion with the US Food and Drug Administration regarding the use of PredictMDx for Brain as a companion diagnostic for the compound cilengitide."

MGMT (O6-methylguanine-DNA methyl transferase) is a key DNA repair enzyme produced by the MGMT gene. When the MGMT gene is methlyated, no MGMT is produced. The more MGMT present in the tumor, the more active the DNA repair. This means therapies that work by inducing DNA damage are less likely to be successful.

* Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. Published ahead of print as 10.1200/JCO.2011.34.8086

About the MGMT Test: PredictMDx for Brain(TM)
PredictMDx for Brain, MDxHealth's most advanced personalized treatment product is a test for assessing patient response to alkylating agents, a class of chemotherapy drugs. The test determines the methylation status of the MGMT gene, which is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy. PredictMDx for Brain has been shown on thousands of patients to help identify those cancer patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents). This patented DNA methylation gene test is attractive for new brain cancer drug developers since they can more easily target their new drugs to the patients who usually do not respond to the traditional alkylating agent drug regime.